Zoetis Inc (NYSE:ZTS) declared a quarterly dividend on Thursday, October 3rd, Zacks reports. Shareholders of record on Tuesday, October 22nd will be given a dividend of 0.164 per share on Monday, December 2nd. This represents a $0.66 annualized dividend and a yield of 0.51%. The ex-dividend date of this dividend is Monday, October 21st.
NYSE ZTS opened at $128.12 on Friday. The company has a debt-to-equity ratio of 2.74, a current ratio of 4.17 and a quick ratio of 2.87. Zoetis has a 1 year low of $78.90 and a 1 year high of $130.20. The company has a market capitalization of $61.35 billion, a PE ratio of 40.93, a P/E/G ratio of 3.18 and a beta of 0.87. The company has a fifty day moving average of $125.65 and a two-hundred day moving average of $114.02.
Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.82 by $0.08. Zoetis had a net margin of 22.74% and a return on equity of 72.86%. The company had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.51 billion. During the same quarter in the prior year, the firm posted $0.77 earnings per share. Zoetis’s revenue for the quarter was up 9.3% on a year-over-year basis. On average, research analysts expect that Zoetis will post 3.57 earnings per share for the current year.
Several equities research analysts have recently weighed in on the stock. ValuEngine downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Argus set a $140.00 target price on shares of Zoetis and gave the stock a “buy” rating in a research note on Wednesday, September 4th. Bank of America cut shares of Zoetis from a “buy” rating to a “neutral” rating and increased their price target for the stock from $111.00 to $120.00 in a report on Monday, July 1st. They noted that the move was a valuation call. Morgan Stanley increased their price target on shares of Zoetis from $100.00 to $136.00 and gave the stock an “equal weight” rating in a report on Monday, September 30th. Finally, Craig Hallum increased their price target on shares of Zoetis from $132.00 to $138.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Eight equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Zoetis presently has a consensus rating of “Buy” and a consensus target price of $123.69.
In other Zoetis news, EVP Roxanne Lagano sold 4,463 shares of the stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $125.99, for a total value of $562,293.37. Following the completion of the transaction, the executive vice president now directly owns 33,190 shares of the company’s stock, valued at $4,181,608.10. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Clinton A. Jr. Lewis sold 6,123 shares of the stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $120.05, for a total transaction of $735,066.15. Following the completion of the transaction, the executive vice president now directly owns 41,698 shares of the company’s stock, valued at $5,005,844.90. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 34,332 shares of company stock valued at $4,258,182. 0.29% of the stock is currently owned by corporate insiders.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Read More: What is Compound Annual Growth Rate (CAGR)?
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.